WO1996009314A2 - Method for loading solid supports for nucleic acid synthesis - Google Patents
Method for loading solid supports for nucleic acid synthesis Download PDFInfo
- Publication number
- WO1996009314A2 WO1996009314A2 PCT/US1995/012196 US9512196W WO9609314A2 WO 1996009314 A2 WO1996009314 A2 WO 1996009314A2 US 9512196 W US9512196 W US 9512196W WO 9609314 A2 WO9609314 A2 WO 9609314A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleoside
- loading
- cpg
- diisopropylcarbodiimide
- solid support
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Definitions
- This invention relates to the field of oligonucleotide synthesis, and, more particularly, to methods of loading mononucleosides on a solid support.
- oligonucleotide methylphosphonates using phosphoramidite chemistry Connolly et al., Biochemistry 23, 3443 (1984), discloses synthesis of oligonucleotide phosphorothioates using phosphoramidite chemistry.
- Jager et al., Biochemistry 27, 7237 (1988) discloses synthesis of oligonucleotide phosphoramidates using phosphoramidite chemistry.
- Solid phase synthesis of ohgonucleotides by the foregoing methods involves the same generalized protocol. Briefly, this approach comprises anchoring the 3'- most nucleoside to a solid support functionalized with amino and or hydroxyl moieties and subsequently adding the additional nucleosides in stepwise fashion. Desired internucleoside linkages are formed between the 3' functional group of the incoming nucleoside and the 5' hydroxyl group of the 5'-most nucleoside of the nascent, support-bound oligonucleotide. Oligonucleotide synthesis generally begins with coupling, or "loading," of the 3 '-most nucleoside of the desired oligonucleotide to a functionalized solid phase support.
- the functionalized support has a plurality of long chain alkyl amines (LCAA) on the surface that serve as sites for nucleoside coupling.
- LCAA long chain alkyl amines
- CPG Controlled pore glass
- CPG supports are generally loaded by attaching a nucleoside-3'-succinate to the support through the succinyl group via an amide bond.
- DCC dicyclohexylcarbo-diimide
- Activation was accomplished by converting the nucleoside-3'-succinate into the symmetrical anhydride (Sproat and Gait, in Oligonucleotide Synthesis: a Practical
- DCC and 1-hydoxybenzotriazole (HOBT) (used in equimolar amounts in a 14:1 dichloromethane/dimethylformamide solvent) resulted in higher loading densities than when DCC was used alone.
- the use of DCC suffers from a number of disadvantages, however. First, DCC is highly toxic. Second, loading was tedious and gave only moderate yields (50-75%). Third, the coupling reactions were lengthy, requiring 3-4 d to make the activated succinates and an additional 4-7 d to couple them to the CPG. And finally, loading values were quite variable, and optimum loading of 30-40 ⁇ mol/g was not always obtained.
- the present invention comprises new and improved methods of loading nucleosides onto a solid support for solid phase oligonucleotide synthesis.
- the methods of the present invention provide several advantages over prior art methods. First, they are more cost efficient. Cheaper, more efficient catalysts and activators used in the present invention result in cost savings as lesser amounts of both catalyst and mononucleoside reactant are required. Savings of approximately 43% have been observed for loading densities of about 70-80 ⁇ mol/g. Second, we are able to eliminate pyridine as a solvent, which not only effects cost savings, but improves the safety of the process, both to the worker and to the environment.
- DIC diisopropylcarbodiimide
- HOBT 1-hydoxybenzotriazole
- DIC 1-hydoxybenzotriazole
- HOBT acts more efficiently and economically than other compounds such as N-hydroxysuccinimide (NHS), paratoluenesulfonic acid (pTSA), and trifluoroacteic acid (TFA).
- NHS N-hydroxysuccinimide
- pTSA paratoluenesulfonic acid
- TFA trifluoroacteic acid
- Loading densities approaching 120 ⁇ mol/g on controlled pore glass (CPG) solid support are readily obtained. Higher loading densities are also observed on other solid supports such as the "TENTAGEL” (Rapp Polymere) and "HLP" (ABI).
- Nitrobenzotriazole acts as efficiently as HOBT, but is somewhat more expensive.
- a method is presented for loading a non-linker-attached nucleoside (i.e., a nucleoside having a free 3' hydroxyl group) onto a solid support bearing a linker groug, e.g., a succinyl moiety.
- a solid support to which a linker has been attached is loaded by contacting it with a nucleoside having a free 3' hydroxyl group in the presence of DIC and HOBT.
- pyridine is eliminated as a solvent.
- Pyridine has generally been used in the loading process as a solvent and to dissolve and wash away all catalyst, unreacted starting materials, and reaction by-products. Because of pyridine's toxicity, its elimination from the loading process increases the safety of the process. In addition, fewer environmentally hazardous wastes are produced. We have found that acetonitrile can be used in place of pyridine without affecting loading efficiencies. Cost savings are also thereby realized.
- Another benefit provided by the methods of the present invention is the ability to adjust loading densities to any desired level, up to the maximum possible empirical value obtainable under optimal conditions. This is useful because equipment limitations (and/or other factors) may restrict the degree of loading to values substantially less than the empirical maximum.
- the present methods can be used to load any nucleoside onto any functionalized solid support.
- the nucleoside may comprise any unmodified base
- the present invention comprises new methods for loading mononucleosides on a solid support.
- loading refers to the chemical linkage of a nucleoside (which will be the 3'-most nucleoside of the oligonucleotide to be synthesized) to a functional group on a solid support. The degree of loading is expressed in ⁇ mol monomer/g solid support.
- a “functional group” is a chemical moiety, such as an amino or hydroxyl moiety, capable of being joined to a nucleoside either directly or via a linker.
- a “functionalized support” is a support having such functional groups.
- the new methods disclosed herein are also significantly less hazardous for the worker and safer for the environment.
- Pyridine is currently used as a reaction solvent and, alone or in combination with other solvents, to wash away unreacted reactants, catalyst, and unwanted reaction by-products.
- the amount of pyridine can be reduced to about 5% in acetonitrile or eliminated completely. Because pyridine is toxic and has an obnoxious odor, the present methods are less hazardous than the prior art methods.
- the present methods also require lesser amounts of reagents, resulting in lesser costs and amounts of waste.
- column loading densities in the range of about 70-80 ⁇ mol/g can be attained using less than about 3 x 10° mol of nucleoside per 25 g of CPG.
- the current methods provide additional cost savings by these means as well.
- savings of about 43% are realized with the new methods for loading densities in the range of about 70-80 ⁇ mol/g.
- the present invention provides methods of loading a functionalized solid support for oligonucleoside synthesis comprising contacting the functionalized solid support with a solvent, diisopropylcarbodiimide, and a nucleoside having a 3' linker group attached at a pH of less than 7.0.
- diisopropylcarbodiimide is used as an activator for the acid catalyzed loading of nucleoside-3 '-succinates.
- the activator forms an intermediate with the terminal carboxylic acid moiety of the nucleoside-3'-succinate, rendering it susceptible to nucleophilic attack by a support- bound amino functional group.
- DIC in the presence of 1-hydroxybenzotirazole (HOBT) is more effective than DEC at activating the succinyl carboxylic acid moiety.
- HOBT is used to catalyze DIC activated loading.
- pyridine as a solvent
- pTSA paratoluenesulfonic acid
- TFA trifluoroacetic acid
- Our experiments demonstrate that the use of HOBT results in loading densities ranging from 30 to 100% greater than those attained using NHS, pTSA, and TFA.
- the amount of HOBT is not critical; it should be sufficient to catalyze the reaction.
- about 0.08 to about 0.16 g HOBT per ml DIC work exceedingly well, although lesser or greater amounts are likely to work just as well. Most preferably, a lesser amount of HOBT is used, generally about 0.08
- nitro-HOBT is used as a catalyst.
- the methods of the present invention can also be used to load a non-linker- attached nucleoside (i.e., a nucleoside having a free 3' hydroxyl group) onto a column bearing a linker groug, e.g., a succinyl moiety.
- a solid support to which a linker, most preferably succinic acid, has been attached is loaded by contacting it with a nucleoside having a free 3' hydroxyl group in the presence of DIC and HOBT.
- the conditions for this reaction are the same as described herein for the loading of nucleosides bearing a 3' linker onto functionalized supports.
- a solid support in which the amount of pyridine used as the reaction solvent and wash solvent is substantially reduced or eliminated.
- pyridine need not be the main solvent in the loading reaction. Any solvent that dissolves the reactants but does not react itself can be used.
- both acetonitrile and dichloromethane are suitable solvents. Acetonitrile is the most preferred solvent.
- a mixture of pyridine with acetonitrile and or dichloromethane is used as the primary solvent for loading nucleosides.
- a small amount of pyridine e.g., about 5%
- the solvent is acetonitrile with very little (e.g., 5% or less) or no pyridine.
- the present invention can be used with any functionalized solid support.
- a number of such supports are known in the art. E.g., Pon in Methods in Molec. Biol, supra. We demonstrate below that both "TENTAGEL S” (Rapp Polymere, Tubingen, Germany)(a support in which polyethyleneglycol spacers are grafted on a gel-type support) and HLP (ABI, Foster City, CA) (a PEG-Polystyrene support) can be loaded with the current methods to extremely high densities.
- CPG is the most preferred support for DNA synthesis.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU37242/95A AU3724295A (en) | 1994-09-23 | 1995-09-22 | Method for loading solid supports for nucleic acid synthesis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/311,156 US5554744A (en) | 1994-09-23 | 1994-09-23 | Method for loading solid supports for nucleic acid synthesis |
US08/311,156 | 1994-09-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996009314A2 true WO1996009314A2 (en) | 1996-03-28 |
WO1996009314A3 WO1996009314A3 (en) | 1996-05-30 |
Family
ID=23205659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/012196 WO1996009314A2 (en) | 1994-09-23 | 1995-09-22 | Method for loading solid supports for nucleic acid synthesis |
Country Status (4)
Country | Link |
---|---|
US (1) | US5554744A (en) |
AU (1) | AU3724295A (en) |
CA (1) | CA2200552A1 (en) |
WO (1) | WO1996009314A2 (en) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6979728B2 (en) * | 1998-05-04 | 2005-12-27 | Baylor College Of Medicine | Articles of manufacture and methods for array based analysis of biological molecules |
US6048695A (en) * | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
AU2001255518A1 (en) * | 2000-06-07 | 2001-12-17 | Baylor College Of Medicine | Compositions and methods for array-based nucleic acid hybridization |
JP3883539B2 (en) * | 2001-09-01 | 2007-02-21 | サムスン エレクトロニクス カンパニー リミテッド | Method for producing hydrogel biochip using radial polyethylene glycol derivative having epoxy group |
US7439346B2 (en) | 2001-10-12 | 2008-10-21 | Perkinelmer Las Inc. | Nucleic acids arrays and methods of use therefor |
AU2002367886B8 (en) * | 2001-10-12 | 2008-08-14 | Perkinelmer Las, Inc. | Compilations of nucleic acids and arrays and methods of using them |
WO2003042697A1 (en) * | 2001-11-14 | 2003-05-22 | Genospectra, Inc. | Biochemical analysis system with combinatorial chemistry applications |
US20030124542A1 (en) * | 2001-12-28 | 2003-07-03 | Spectral Genomics, Inc. | Methods for mapping the chromosomal loci of genes expressed by a cell |
US20030166282A1 (en) | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
ATE529512T1 (en) | 2002-02-01 | 2011-11-15 | Life Technologies Corp | DOUBLE STRANDED OLIGONUCLEOTIDES |
US20050009051A1 (en) * | 2002-09-27 | 2005-01-13 | Board Of Regents, The University Of Texas | Diagnosis of mould infection |
WO2004073624A2 (en) | 2003-02-14 | 2004-09-02 | The Curators Of The University Of Missouri | Contraceptive methods and compositions related to proteasomal interference |
AU2005216549A1 (en) * | 2004-02-27 | 2005-09-09 | President And Fellows Of Harvard College | Polony fluorescent in situ sequencing beads |
EP1771563A2 (en) | 2004-05-28 | 2007-04-11 | Ambion, Inc. | METHODS AND COMPOSITIONS INVOLVING MicroRNA |
WO2006031955A2 (en) | 2004-09-14 | 2006-03-23 | The Regents Of The University Of Colorado, A Body Corporate | Method for treatment with bucindolol based on genetic targeting |
ES2534304T3 (en) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedures and compositions involving miRNA and miRNA inhibitor molecules |
US20090264635A1 (en) * | 2005-03-25 | 2009-10-22 | Applera Corporation | Methods and compositions for depleting abundant rna transcripts |
EP2487240B1 (en) | 2006-09-19 | 2016-11-16 | Interpace Diagnostics, LLC | Micrornas differentially expressed in pancreatic diseases and uses thereof |
KR101588736B1 (en) | 2008-01-10 | 2016-01-26 | 리서치 디벨롭먼트 파운데이션 | Vaccines and diagnostics for Ehrlichia chaffeensis |
JP5674476B2 (en) | 2008-01-25 | 2015-02-25 | ピー53 インコーポレイテッド | P53 biomarker |
EP2990487A1 (en) | 2008-05-08 | 2016-03-02 | Asuragen, INC. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
US20100047876A1 (en) * | 2008-08-08 | 2010-02-25 | President And Fellows Of Harvard College | Hierarchical assembly of polynucleotides |
CN102272157B (en) | 2008-11-07 | 2015-11-25 | 研究发展基金会 | For suppressing composition and the method for the formation of CRIPTO/GRP78 mixture and signal |
JP5651125B2 (en) | 2008-12-10 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | MEK mutations that confer resistance to MEK inhibitors |
JP2012515532A (en) | 2009-01-20 | 2012-07-12 | ラモット アット テル アビブ ユニバーシティ, リミテッド | MIR-21 promoter driven target cancer treatment |
US20110045080A1 (en) * | 2009-03-24 | 2011-02-24 | William Marsh Rice University | Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto |
CA2766351C (en) | 2009-06-29 | 2018-02-27 | Luminex Corporation | Chimeric primers with hairpin conformations and methods of using same |
US20120238509A1 (en) | 2009-08-28 | 2012-09-20 | Research Development Foundation | Urocortin 2 analogs and uses thereof |
WO2011032088A1 (en) | 2009-09-11 | 2011-03-17 | Arca Biopharma, Inc. | Polymorphisms in the pde3a gene |
ES2587191T3 (en) | 2009-12-23 | 2016-10-21 | Arca Biopharma, Inc. | Methods and compositions for cardiovascular diseases and conditions |
WO2011099664A1 (en) | 2010-02-12 | 2011-08-18 | 엠앤디(주) | Probe for hpv genotype diagnosis and analysis method thereof |
MX340392B (en) | 2010-02-25 | 2016-07-06 | Dana Farber Cancer Inst Inc | Braf mutations conferring resistance to braf inhibitors. |
EP2542678B1 (en) | 2010-03-04 | 2017-04-12 | InteRNA Technologies B.V. | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT |
US20130131148A1 (en) | 2010-04-12 | 2013-05-23 | Noam Shomron | Micro-rna for cancer diagnosis, prognosis and therapy |
EP3333259B1 (en) | 2010-06-09 | 2021-02-24 | Dana Farber Cancer Institute, Inc. | A mek1 mutation conferring resistance to raf and mek inhibitors |
CA2804599C (en) | 2010-07-06 | 2023-01-31 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
GB2497912B (en) | 2010-10-08 | 2014-06-04 | Harvard College | High-throughput single cell barcoding |
EP2640851A2 (en) | 2010-11-17 | 2013-09-25 | Asuragen, Inc. | Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
RU2615117C2 (en) | 2011-02-03 | 2017-04-04 | Мирна Терапетикс, Инк. | Double-stranded rna molecule for mir-34a activity in cell |
AU2012212105A1 (en) | 2011-02-03 | 2013-09-12 | Mirna Therapeutics, Inc. | Synthetic mimics of miR-124 |
US9018188B2 (en) | 2011-09-13 | 2015-04-28 | Ottawa Hospital Research Institute | MicroRNA inhibitors |
WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
EP2766498B1 (en) | 2011-10-14 | 2019-06-19 | President and Fellows of Harvard College | Sequencing by structure assembly |
US20130157884A1 (en) | 2011-10-26 | 2013-06-20 | Asuragen, Inc. | Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts |
ES2886147T3 (en) | 2011-12-22 | 2021-12-16 | Interna Tech B V | MiRNAs for the treatment of head and neck cancer |
WO2013184754A2 (en) | 2012-06-05 | 2013-12-12 | President And Fellows Of Harvard College | Spatial sequencing of nucleic acids using dna origami probes |
CN108875312A (en) | 2012-07-19 | 2018-11-23 | 哈佛大学校长及研究员协会 | Utilize the method for nucleic acid storage information |
WO2014045126A2 (en) | 2012-09-18 | 2014-03-27 | Uti Limited Partnership | Treatment of pain by inhibition of usp5 de-ubiquitinase |
US20140100124A1 (en) | 2012-10-04 | 2014-04-10 | Asuragen, Inc. | Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions |
US9476089B2 (en) | 2012-10-18 | 2016-10-25 | President And Fellows Of Harvard College | Methods of making oligonucleotide probes |
US10201556B2 (en) | 2012-11-06 | 2019-02-12 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway |
WO2014116721A1 (en) | 2013-01-22 | 2014-07-31 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Geminiviral vector for expression of rituximab |
EP2961853B1 (en) | 2013-02-28 | 2018-09-19 | The Board of Regents of The University of Texas System | Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers |
EP2971184B1 (en) | 2013-03-12 | 2019-04-17 | President and Fellows of Harvard College | Method of generating a three-dimensional nucleic acid containing matrix |
EP3404116B1 (en) | 2013-03-15 | 2022-10-19 | The University of Chicago | Methods and compositions related to t-cell activity |
US20150098940A1 (en) | 2013-10-03 | 2015-04-09 | Oklahoma Medical Research Foundation | Biomarkers for Systemic Lupus Erythematosus Disease Activity, and Intensity and Flare |
WO2015070050A1 (en) | 2013-11-08 | 2015-05-14 | Baylor Research Institute | Nuclear loclization of glp-1 stimulates myocardial regeneration and reverses heart failure |
WO2016134293A1 (en) | 2015-02-20 | 2016-08-25 | Baylor College Of Medicine | p63 INACTIVATION FOR THE TREATMENT OF HEART FAILURE |
CA3019635A1 (en) | 2016-03-31 | 2017-10-05 | Baylor Research Institute | Angiopoietin-like protein 8 (angptl8) |
MX2019003070A (en) | 2016-09-16 | 2019-10-14 | Bio Path Holdings Inc | Combination therapy with liposomal antisense oligonucleotides. |
AU2018358016A1 (en) | 2017-11-03 | 2020-05-07 | Interna Technologies B.V. | MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
AU2019272961A1 (en) | 2018-05-25 | 2021-01-21 | Arca Biopharma Inc. | Methods and compositions involving bucindolol for the treatment of atrial fibrillation |
WO2022097157A2 (en) | 2020-11-09 | 2022-05-12 | 1E Therapeutics, Ltd. | Catalytic sequence based methods of treating or preventing bacterial infections |
IL304047A (en) | 2020-12-28 | 2023-08-01 | 1E Therapeutics Ltd | P21 mrna target areas for silencing |
IL304068A (en) | 2020-12-28 | 2023-08-01 | 1E Therapeutics Ltd | P21 mrna targeting dnazymes |
JP2024516548A (en) | 2021-04-08 | 2024-04-16 | ジョスリン ダイアビーティス センター インコーポレイテッド | Methods for diagnosing and predicting renal dysfunction |
WO2024015766A1 (en) | 2022-07-12 | 2024-01-18 | Topogene Inc. | Scalable, submicron-resolution replication of dna arrays |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991013080A1 (en) * | 1990-02-20 | 1991-09-05 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
US5204455A (en) * | 1989-06-15 | 1993-04-20 | Froehler Brian C | Monomethoxytrityl protected oligonucleotides bound to a solid support |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149798A (en) * | 1989-04-06 | 1992-09-22 | Worcester Foundation For Experimental Biology | Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses |
-
1994
- 1994-09-23 US US08/311,156 patent/US5554744A/en not_active Expired - Fee Related
-
1995
- 1995-09-22 WO PCT/US1995/012196 patent/WO1996009314A2/en active Application Filing
- 1995-09-22 CA CA002200552A patent/CA2200552A1/en not_active Abandoned
- 1995-09-22 AU AU37242/95A patent/AU3724295A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204455A (en) * | 1989-06-15 | 1993-04-20 | Froehler Brian C | Monomethoxytrityl protected oligonucleotides bound to a solid support |
WO1991013080A1 (en) * | 1990-02-20 | 1991-09-05 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
Non-Patent Citations (4)
Title |
---|
J. ORG. CHEM., vol. 58, 1993 pages 2223-31, J.M. LAWLOR ET AL. 'The synthesis of oligonucleotide-polyamide conjugate molecules suitable as PCR primers' cited in the application * |
NUCLEOSIDES, NUCLEOTIDES, vol. 12, 1993 pages 967-71, E. PEDROSO ET AL. 'Predictable and reproducible yields in the anchoring of DMT-nucleoside-succinates to highly loaded aminoalkyl-polystyrene resins' cited in the application * |
SYNTH. COMMUN., vol. 25, no. 22, 1995 pages 3671-9, N. BHONGLE AND J.Y. TANG 'A convenient and practical method for dervatization of solid supports for nucleic acid synthesis ' * |
TETRAHEDR. LETT., vol. 34, 1993 pages 8169-72, A. GUZAEV ET AL. 'Synthesis of 3'-functionalized oligonucleotides on a single solid support' * |
Also Published As
Publication number | Publication date |
---|---|
CA2200552A1 (en) | 1996-03-28 |
WO1996009314A3 (en) | 1996-05-30 |
AU3724295A (en) | 1996-04-09 |
US5554744A (en) | 1996-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5554744A (en) | Method for loading solid supports for nucleic acid synthesis | |
Scaringe | RNA oligonucleotide synthesis via 5′-silyl-2′-orthoester chemistry | |
US4659774A (en) | Support for solid-phase oligonucleotide synthesis | |
EP1343802B1 (en) | Process for the preparation of oligonucleotides | |
AU712779C (en) | Method for solution phase synthesis of oligonucleotides | |
EP0843684B1 (en) | Universal solid supports and methods for their use | |
JP2001505543A (en) | Solid phase synthesis method | |
JP3684182B2 (en) | New reagents for labeling nucleic acids | |
WO1997031009A1 (en) | Solid phase synthesis of oligonucleotide n3'→p5' phosphoramidates | |
CA2277415A1 (en) | Method for solution phase synthesis of oligonucleotides and peptides | |
Muller et al. | Current strategies for the synthesis of RNA | |
US5668268A (en) | Passivated polymer supports for nucleic acid synthesis | |
JP2004346071A (en) | Solid support reagent for synthesizing 3'-nitrogen containing polynucleotide | |
US20040215010A1 (en) | Universal solid supports for solid phase oligosynthesis and methods for their preparation and use | |
US7098326B2 (en) | Methods for the integrated synthesis and purification of oligonucleotides | |
KR20200035267A (en) | Improved process for manufacturing Imetteel start | |
WO1998016540A1 (en) | Improved coupling activators for oligonucleotide synthesis | |
EP0898575A2 (en) | A combinatorial protecting group strategy for multifunctional molecules | |
US7705136B2 (en) | Synthesis of 3′-, or 5′-, or internal methacrylamido-modified oligonucleotides | |
US20040010081A1 (en) | Novel strategy for synthesizing polymers in surfaces | |
Tetzlaff et al. | Synthesis and hydrolytic stability of 5′-aminoacylated oligouridylic acids | |
TW202300504A (en) | Universal linker reagents for dna synthesis | |
AU703509C (en) | Solid phase synthesis of oligonucleotide N3'-P5' phosphoramidates | |
Wang et al. | Affinity chromatography using enzymatically synthesized nucleotide-containing DNA binding polymers | |
EP0839829A2 (en) | Universal solid support oligonucleotide reagents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2200552 Country of ref document: CA Ref country code: CA Ref document number: 2200552 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 809026 Date of ref document: 19970714 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |